Back to Authors

Shahi, Mahdiyeh

0009-0005-0128-0379

Mayo Clinic

Department of Chemistry, Purdue University, West Lafayette, IN 47907.

Citations 2

Metabolite ratiomics: Rapid diagnosis and classification of gliomas for intraoperative application during brain surgery
Shahi, Mahdiyeh , Michaelides, Loizos , Moniz Garcia, Diogo, Basil, Aleeshba N, Quinones-Hinojosa, Alfredo , Cooks, R Graham

Proceedings of the National Academy of Sciences | September 30, 2026 | Volume: 123 | Issue: 40 | Pages: No page available

10.1073/pnas.2616216123 Get It

Gliomas are diffusely infiltrative, requiring accurate and sensitive diagnostic tools during surgical resection. Mutations in isocitrate dehydrogenase enzyme (IDH) alter its normal activity and result in accumulation of a unique oncometabolite, 2-hydroxyglutarate (2HG), in tumor cells. However, IDH-wild-type (IDH-wt) gliomas are more common and typically more aggressive. Here, 86 human brain samples were analyzed by syringe touch spray mass spectrometry to evaluate molecular alterations in gliomas. Tandem mass spectrometry (MS/MS) experiments were performed to minimize isobaric and isomeric interferences, and a ratiometric approach (using only signals for endogenous compounds) was employed to improve reliability of the measurements. Multiple ratios for pairs of metabolite signal intensities were found to differentiate tumor samples from nontumor tissue and they stratified glioma subtypes by IDH mutation status and by tumor grade, with several ratios showing 100% agreement with independent clinical assignments ( P < 0.0001, Mann–Whitney U test). Increased carnitine relative abundances were found across all glioma subtypes. Importantly, α-aminoadipate was significantly elevated in grade 4 glioma, which may correlate with increased tumor malignancy. Grade 3 gliomas showed markedly higher 2HG abundance than grade 4 samples. In addition, a selection of ratios showed a linear trend with varying tumor cell percentage. Overall, the multiple metabolic ratio alterations indicate a high degree of heterogeneity among glioma subtypes. Furthermore, there are metabolites that can differentiate glioma from nontumor tissue and this measurement can be made by a simple ratiometric method which has potential to be used intraoperatively for margin assessment without diverging from standard of care.
Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry
Hua, Wei , Brown, Hannah Marie , Fang, Xinqi , Shahi, Mahdiyeh , Chen, Rong , Jiao, Bin , Wang, Nan , Xu, Hao , Wang, Xiaowen , Zhang, Jinsen , Wang, Qijun , Ye, Dan , Chaichana, Kaisorn L. , Mao, Ying , Quiñones‐Hinojosa, Alfredo , Shahi, Mahdiyeh , Garcia, Diogo Moniz-, Chaichana, Kaisorn, Cooks, R Graham , Quinones-Hinojosa, Alfredo , Zhang, Wenpeng , Wu, Junhan , Zhang, Haoyue , Jiao, Bin, Fu, Minjie , Zhang, Xin , Zhu, Wei Ping , Moniz‐Garcia, Diogo , Cooks, R. Graham , Ouyang, Zheng

Proceedings of the National Academy of Sciences | June 2, 2024 | Volume: 121 | Issue: 23 | Pages: No page available

10.1073/pnas.2318843121 Get It

The development and performance of two mass spectrometry (MS) workflows for the intraoperative diagnosis of isocitrate dehydrogenase (IDH) mutations in glioma is implemented by independent teams at Mayo Clinic, Jacksonville, and Huashan Hospital, Shanghai. The infiltrative nature of gliomas makes rapid diagnosis necessary to guide the extent of surgical resection of central nervous system (CNS) tumors. The combination of tissue biopsy and MS analysis used here satisfies this requirement. The key feature of both described methods is the use of tandem MS to measure the oncometabolite 2-hydroxyglutarate (2HG) relative to endogenous glutamate (Glu) to characterize the presence of mutant tumor. The experiments i) provide IDH mutation status for individual patients and ii) demonstrate a strong correlation of 2HG signals with tumor infiltration. The measured ratio of 2HG to Glu correlates with IDH-mutant (IDH-mut) glioma ( P < 0.0001) in the tumor core data of both teams. Despite using different ionization methods and different mass spectrometers, comparable performance in determining IDH mutations from core tumor biopsies was achieved with sensitivities, specificities, and accuracies all at 100%. None of the 31 patients at Mayo Clinic or the 74 patients at Huashan Hospital were misclassified when analyzing tumor core biopsies. Robustness of the methodology was evaluated by postoperative re-examination of samples. Both teams noted the presence of high concentrations of 2HG at surgical margins, supporting future use of intraoperative MS to monitor for clean surgical margins. The power of MS diagnostics is shown in resolving contradictory clinical features, e.g., in distinguishing gliosis from IDH-mut glioma.